Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

被引：0
|
作者：
Caroland, Kailey
Shi, Changyou
Lo, Hui-Wen
Lin, Jiayuh
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Investigating CDK4/6 inhibition in triple-negative breast cancer.
    Guo, Qiuchen
    Goreczny, Gregory J.
    Maynard, Adam
    Spasic, Milos
    McAllister, Sandra S.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 40 - 40
  • [2] CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    MEDCOMM, 2021, 2 (04): : 514 - 530
  • [3] Investigating CDK4/6 inhibition in triple negative breast cancer
    Guo, Qiuchen
    Goreczny, Gregory J.
    Spasic, Milos
    Maynard, Adam
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
    Jennifer Y. Ge
    Shaokun Shu
    Mijung Kwon
    Bojana Jovanović
    Katherine Murphy
    Anushree Gulvady
    Anne Fassl
    Anne Trinh
    Yanan Kuang
    Grace A. Heavey
    Adrienne Luoma
    Cloud Paweletz
    Aaron R. Thorner
    Kai W. Wucherpfennig
    Jun Qi
    Myles Brown
    Piotr Sicinski
    Thomas O. McDonald
    David Pellman
    Franziska Michor
    Kornelia Polyak
    Nature Communications, 11
  • [5] Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
    Ge, Jennifer Y.
    Shu, Shaokun
    Kwon, Mijung
    Jovanovi, Bojana
    Murphy, Katherine
    Gulvady, Anushree
    Fassl, Anne
    Trinh, Anne
    Kuang, Yanan
    Heavey, Grace A.
    Luoma, Adrienne
    Paweletz, Cloud
    Thorner, Aaron R.
    Wucherpfennig, Kai W.
    Qi, Jun
    Brown, Myles
    Sicinski, Piotr
    McDonald, Thomas O.
    Pellman, David
    Michor, Franziska
    Polyak, Kornelia
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [6] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [7] CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Goel, Shom
    Tolaney, Sara M.
    LANCET ONCOLOGY, 2019, 20 (11): : 1479 - 1481
  • [8] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [9] Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
    Wang, Runtian
    Xu, Kun
    Gao, Fangyan
    Huang, Jinyi
    Guan, Xiaoxiang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [10] Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Hu, Ye
    Gao, Jiyue
    Wang, Meiling
    Li, Man
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5223 - 5237
12345